News of Note—Aurobindo recalls tainted valsartan APIs; Almac adds peptide capacity


> India’s Aurobindo, which earlier recalled 22 batches of its irbesartan API because it contained N-nitrosodiethylamine (NDEA), is now recalling 80 lots of amlodipine valsartan tablets USP, valsartan HCTZ tablets and valsartan tablets for the same reason. Release

> CDMO Almac Group has added a second line for high throughput GMP peptide manufacturing at its facility in Edinburgh, Scotland, to meet demand from drugmakers working on patient-specific, individualized cancer vaccines. Release

> Cambrex, which makes small molecule generic APIs, has completed its $252 million buyout of Avista Pharma Solutions, a four-facility contract development, manufacturing and testing organization. Release  

> Three former Hikma manufacturing plants in Eatontown, New Jersey, have been acquired by a developer and private investment group, which will sell the equipment and convert the buildings to another use. Release